Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT

Blood (2024) 143 (4): 370–374.

https://doi.org/10.1182/blood.2023021307

Published: 2024

Includes: Supplemental data

Journal Articles

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

Blood (2023) 142 (26): 2305–2314.

https://doi.org/10.1182/blood.2023022136

Published: 2023

Includes: Supplemental data

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Study on the Changes of Immune Cells in the Evolution of Myelodysplastic Syndromes

Jing Wang, Xiaoyuan Zhang, Yue Zhao, Jingjing Zhang, Yibin Zhou, Li Hou

Blood (2023) 142 (Supplement 1): 5381.

https://doi.org/10.1182/blood-2023-179797

Published: 2023

Journal Articles

1q21+ Is Associated with Poor Prognosis in Newly Diagnosed Multiple Myeloma Patients with Extramedullary Disease: A Retrospective Study

Shuang Gao, Fei Dong, Ping Yang, Yingtong Chen, Yanfang Wang, Jing Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 6685.

https://doi.org/10.1182/blood-2023-184339

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Wen-Jing Yu, Ying Wu, Qi Chen, Xiaolu Zhu, Xu-Ying Pei, Jin-Song Jia, Jing Wang, Xiao-Su Zhao, Ying-Jun Chang, Yue-Yun Lai, Hong-Xia Shi, Guo-Rui Ruan, Ya-Zhen Qin, Xiao-Hong Liu, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2023-184665

Published: 2023

Journal Articles

The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Mulitiple Myeloma

Jiangbo Zhang, Hua Xue, Rong Fu, Jing Wang, Songying Zhao, Huimei Guo, Jia Liu, Jianmei Xu, Yao Liu

Blood (2023) 142 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2023-188179

Published: 2023

Journal Articles

Evaluating the Effectiveness of Risk Adjustment Using Dynamic Frailty Assessment in Treating Newly Diagnosed Multiple Myeloma in Elderly Patients

Jianmei Xu, Hua Xue, Songying Zhao, Jing Wang, Huimei Guo, Jiangbo Zhang, Jia Liu, Mingjie Tian, Luoming Hua, Mingfeng Zhao

Blood (2023) 142 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2023-185684

Published: 2023

Journal Articles

Different Sources of Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: Relationship between Immune Reconstitution, Graft-Versus-Host Disease, and Viral Infections

Jianyun Liao, Chaoke Bu, Lan He, Huaying Liu, Zhiyong Peng, Weiwei Zhang, Haoran Tang, Jing Wang, Zimao Lu, Yanfeng Zhou, Yuqian Xia, Yuelin He, Chunfu Li

Blood (2023) 142 (Supplement 1): 7093.

https://doi.org/10.1182/blood-2023-188109

Published: 2023

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Jing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiao-su Zhao, Jinsong JIA, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wen-Jing Yu, Xiaojun Huang

Blood (2023) 142 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2023-174600

Published: 2023

Journal Articles

Efficacy Analysis of Ixazomib-Based Regimens Based on Dynamic Frailty Assessment in Elderly and Frail Patients with Newly Diagnosed Multiple Myeloma

Jianmei Xu, Hua Xue, Songying Zhao, Jing Wang, Huimei Guo, Jiangbo Zhang, Jia Liu, Luoming Hua, Mingjie Tian, Mingfeng Zhao

Blood (2023) 142 (Supplement 1): 6690.

https://doi.org/10.1182/blood-2023-185230

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Blood (2023) 142 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2023-184870

Published: 2023

Journal Articles

Retrospective Analysis of Four Frailty Assessment Tools in Elderly Patients with Multiple Myeloma

Yujun Li, Jiangbo Zhang, Jianmei Xu, Huimei Guo, Jing Wang, Songying Zhao, Liyang Liu, Hua Xue, Yao Liu

Blood (2023) 142 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2023-184676

Published: 2023

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2023-184348

Published: 2023

Journal Articles

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2023) 142 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2023-184372

Published: 2023

Journal Articles

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Xiaoyan Ke, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2023-183096

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, Keiko Akagi, Amishi U. Vora, Hans C. Lee, Krina K. Patel, Pei Lin, Bo Jiang, Yang Song, Maura L. Gillison, Sheeba K. Thomas, Donna M. Weber, Lixia Diao, Jing Wang, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 752.

https://doi.org/10.1182/blood-2023-188016

Published: 2023

NARROW

Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Study on the Changes of Immune Cells in the Evolution of Myelodysplastic Syndromes

1q21+ Is Associated with Poor Prognosis in Newly Diagnosed Multiple Myeloma Patients with Extramedullary Disease: A Retrospective Study

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Mulitiple Myeloma

Evaluating the Effectiveness of Risk Adjustment Using Dynamic Frailty Assessment in Treating Newly Diagnosed Multiple Myeloma in Elderly Patients

Different Sources of Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: Relationship between Immune Reconstitution, Graft-Versus-Host Disease, and Viral Infections

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Efficacy Analysis of Ixazomib-Based Regimens Based on Dynamic Frailty Assessment in Elderly and Frail Patients with Newly Diagnosed Multiple Myeloma

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

11q Gain with t(11;14) or Alone Were Associated with Poor Prognosis in Newly-Diagnosed Multiple Myeloma Patients By SNP-Array Analysis and FISH

Retrospective Analysis of Four Frailty Assessment Tools in Elderly Patients with Multiple Myeloma

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only